In 2007 Sorafenib was the first VEGFR TKI (vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitor (TKI)) to be approved in advanced HCC, and it is used as standard treatment for patients who have no/mild cirrhosis. The gene discussed is KDR; the disease is Cirrhosis.